- Open Access
Cellular RelB interacts with the transactivator Tat and enhance HIV-1 expression
© The Author(s) 2018
- Received: 16 March 2018
- Accepted: 15 September 2018
- Published: 21 September 2018
Human immunodeficiency virus type 1 (HIV-1) Tat protein plays an essential role in HIV-1 gene transcription. Tat transactivates HIV-1 long terminal repeat (LTR)-directed gene expression through direct interactions with the transactivation-responsive region (TAR) element and other cis elements in the LTR. The TAR-independent Tat-mediated LTR transactivation is modulated by several host factors, but the mechanism is not fully understood.
Here, we report that Tat interacts with the Rel homology domain of RelB through its core region. Furthermore, RelB significantly increases Tat-mediated transcription of the HIV-1 LTR and viral gene expression, which is independent of the TAR. Both Tat and RelB are recruited to the HIV-1 promoter, of which RelB facilitates the recruitment of Tat to the viral LTR. The NF-κB elements are key to the accumulation of Tat and RelB on the LTR. Knockout of RelB reduces the accumulation of RNA polymerase II on the LTR, and decreases HIV-1 gene transcription. Together, our data suggest that RelB contributes to HIV-1 transactivation.
Our results demonstrate that RelB interacts with Tat and enhances TAR-independent activation of HIV-1 LTR promoter, which adds new insights into the multi-layered mechanisms of Tat in regulating the gene expression of HIV-1.
Human immunodeficiency virus type 1 (HIV-1) encodes a transcriptional activator protein Tat, which regulates multiple stages of HIV-1 transcription, robustly increases viral RNA synthesis, and allows efficient viral replication [1–3]. Transcription of integrated proviral HIV-1 DNA is initiated from the long terminal repeat (LTR). The LTR is a strong RNA polymerase II (RNA Pol II) promoter that contains many binding sites for cellular transcription factors [3–5]. Tat potently transactivates HIV-1 LTR-directed gene expression by directly interacting with the nascent RNA stem-loop known as the transactivation-responsive region (TAR) and promoting transcription elongation . In addition to TAR, several cis-acting regulatory elements in the HIV-1 LTR are also essential for Tat activation. These elements include the proximal enhancer element containing two NF-κB binding motifs, and the core element containing three Sp1-binding sites, a TATA element, and an initiator element [3, 7–11]. Das et al. generated an HIV-1 proviral DNA construct that does not depend on the Tat-TAR interaction for transcription and demonstrated that Tat remains important for viral transcription via the Sp1-binding sites in the U3 region of LTR promoter [12, 13]. It is therefore posited that Tat is able to promote viral replication at the very early stage of HIV-1 transcription before TAR is formed . Multiple host cellular factors such as Sp1, nuclear factor κB (NF-κB), TATA-binding protein (TBP), nuclear factor of activated T cells (NFAT), are essential for the TAR-independent transcriptional activity of Tat [7, 9, 15, 16].
NF-κB binding sites are found in the enhancer region of all primate lentiviral LTRs, although the number may vary between different subtypes of HIV-1. Most subtypes of pandemic HIV-1 group M strains (A, B, D, F, G, H, J, and K) contain two NF-κB binding sites located − 104 to − 80 bp upstream of the transcription start site within the 5′ LTR. In contrast, human immunodeficiency virus type 2 (HIV-2) and the A/E recombinant of HIV-1 contain a single NF-κB binding site. Subtype C strains typically contain three binding sites of NF-κB in their enhancer regions [17, 18]. It is known that HIV-1 transcription can be enhanced by activation of the NF-κB pathway [19, 20]. Earlier studies have shown that Tat can directly bind to the NF-κB binding sites [21, 22] and activate NF-κB via physical interactions with IκBα and RelA at the initiation step of transcription .
To further illuminate cellular co-factors that assist the role of Tat in transcription initiation, we screened for Tat-binding cellular protein using a human B cell library in a yeast two-hybrid assay, and RelB was one of those proteins that were identified. RelB is a member of the NF-κB family of transcription factors (p50/p105, p52/p100, RelA, RelB and c-Rel) [24, 25]. It is structurally and functionally different from the other two transcriptionally active members, RelA and c-Rel . In addition to a Rel homology domain (RHD) and a transactivation domain (TAD), RelB also has an N-terminal leucine zipper domain that is not present in other NF-κB family members . RelB binds to the target promoters through interaction with other proteins (e.g. p52, p50 and RelA). Compared to other members of the NF-κB family, the mechanism of action of the RelB subunit has remained elusive [27, 28]. Moreover, several viral components, such as HIV-1 Vpr, bovine foamy virus (BFV) transactivator BTas, and human T cell leukemia virus type 1 (HTLV-1) Tax1, have been demonstrated to interact with RelB to facilitate virus replication or contribute to the pathogenesis of the disease [29–31]. However, in these studies, the role of interaction between Tat and RelB in activating the LTR promoter was not investigated.
Our study shows that RelB interacts with Tat, and they are recruited to the HIV-1 promoter. The NF-κB elements are key to the association of Tat and RelB with the LTR. RelB regulates proviral DNA transcription by enhancing the effect of Tat in activating LTR transcription independent of TAR. Thus, we have identified RelB interacts with Tat and enhances the TAR-independent activation of HIV-1 gene expression.
DNA constructs pCMV-Tat , pFlag-Tat, pMyc-Tat, pEGFP-Tat , pCMV-RelB, pFlag-RelB, pMyc-RelB , pCMV-p100 , pHIV-1-LTR-luc [30, 32], pQCXIP (pRetroX-Tight-Pur retroviral vector, Clontech), pMLV-Gag-Pol and pVSV-G were described previously . HIV-1 proviral DNA clone pNL4-3.Luc.env− was a gift from Johnny J He . This proviral DNA construct was derived from the NL4-3 strain with env gene inactivated and the firefly luciferase gene in place of HIV-1 nef . The pNLENY1-ES-IRES construct was kindly provided by Dr. David Levy (University of Alabama at Birmingham, USA) . Plasmids pLentiCRISPR (pXPR_001) and psPAX2 (AddGene 12260) were kindly provided by Dr. Feng Zhang (MIT, USA) . Plasmids pHA-RelB, and pQC-RelB were constructed by PCR amplification of pCMV-RelB and cloning of PCR products into pCMV-3HA, or pQCXIP vectors. pHA-Tat was constructed by inserting Tat with a C-terminal HA tag into the pQCXIP retroviral vector. RelB deletion mutants were described previously . Tat deletion mutants were engineered by inserting the respective PCR fragment into pEGFP-C1. Constructs of pHIV-1-LTR-luc deletions were generated through PCR using pHIV-1-LTR-luc as a template and cloned into pGL3-basic (promega, CAT# E1751), that were described previously . Plasmids pHIV-1-LTR-mutTAR, pHIV-1-LTR-mutNFκB, and pHIV-1-LTR-mutTAR-mutNFκB were generated using PCR-based mutagenesis. The PCR primers are listed in Additional file 1: Table 1. The sequences of all new constructs were confirmed by sequencing.
Cell culture and transfection
HEK 293T (ATCC, CRL-11268G-1), HeLa (ATCC, CCL-2), and TZM-bl cells (NIH, CAT# 8129) [39–41] were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco) with 10% fetal bovine serum (FBS, Hyclone). Jurkat (ATCC, TIB-152), J-Lat A72 (NIH, CAT# 9856) [42, 43], and peripheral blood mononuclear cells (PBMCs) were maintained in RPMI 1640 (Corning) with 10% FBS and 2.4 mM l-glutamine (Gibco). Cells were maintained in a humidified atmosphere containing 5% CO2 at 37 °C. HeLa, TZM-bl, HEK 293T cells were transfected by polyethylenimine (PEI, Poly-sciences, CAT# 23966) or Lipofectamine 2000 (Invitrogen, CAT# 11668-019) in accordance with the manufacturer’s instructions.
PBMCs were isolated from buffy coat from healthy blood donors by histopaque and percoll gradient centrifugation, and were activated with phytohemagglutinin (PHA, 5 μg/ml) (Sigma, CAT# L1668) and IL-2 (20 U/ml) (Pepro Tech, CAT# 200-02) for 24 h before virus infection . The siRNAs (Gene Pharma, Additional file 1: Table 2) were transfected into PBMCs by Lipofectamine RNAiMAX (Invitrogen, CAT# 13778-030) in accordance with the manufacturer’s instructions.
Antibodies and reagents
Anti-RelB (CAT# 10544), anti-p52 (CAT# 37359), and rabbit anti-Flag (CAT# H2368) antibodies were purchased from Cell Signaling Technology. Mouse anti-Myc (CAT# 05-724), anti-p24 (CAT# MAB880-A), anti-RNA Pol II (CAT# 05-623B), normal mouse IgG (CAT# 12-371B) and normal rabbit IgG (CAT# 12-370) were from Millipore. Mouse anti-Flag (M2) (CAT# F1804), mouse anti-HA (CAT# H3663), and rabbit anti-EGFP (CAT# G1544) antibodies were obtained from Sigma. Anti-GAPDH (CAT# sc-32233), anti-Tubulin (CAT# sc-32293), rabbit anti-HA (CAT# sc-805), rabbit anti-Myc (CAT# sc-789), mouse anti-EGFP (CAT# sc-9996) and horseradish peroxidase-conjugated secondary antibodies (CAT# sc-2005 and sc-2004) were from Santa Cruz Biotechnology. FITC-conjugated goat anti-mouse IgG (CAT# 115-095-005) and TRITC-conjugated goat anti-rabbit IgG (CAT# 111-025-003) were from Jackson Immuno Research. RNase A (CAT# 20-297) was purchased from Millipore. DAPI (4′,6-diamidino-2-phenylindole) (CAT# D8417) and Phorbol 12-myristate 13-acetate (PMA) (CAT# P8139) were purchased from Sigma.
Generation of stably transduced cell lines
First, HA-Tat or RelB was cloned into the pQCXIP. Then, retrovirus particles were prepared by transfecting HEK 293T cells (0.5 × 106) with 1 μg pMLV-Gag-pol, 0.5 μg pVSV-G, and 1 μg pQCXIP DNA constructs. After 48 h, supernatants were collected and centrifuged at 3000 rpm to remove cell debris. HeLa, HEK 293T, Jurkat, or J-Lat A72 cells were infected with the harvested virus-like particles (VLPs) in the presence of 5 μg/ml polybrene by spinoculation at 450×g for 30 min at room temperature. Forty-eight hours after infection, cells were subcultured in selection medium containing 2 μg/ml puromycin (Sigma, CAT# P8833). Overexpressing efficiency was assessed by western blotting using specific antibodies. Design and construct sgRNA for RelB knockout (RELB−/−) are as follows: sgRNA1#: forward (5′-CACCGCCCGCGTGCATGCTTCGGTC-3′); reverse (5′-AAACGACCGAAGCATGCACGCGGGC-3′); sgRNA2#: forward (5′-CACCGTCGCCGCGTCGCCAGACCGC-3′); reverse (5′-AAACGCGGTCTGGCGACGCGGCGAC-3′). sgRNA was cloned into the pLentiCRISPR vector. To produce lentiviruses, pLentiCRISPR (with sgRNA cloned) was cotransfected into HEK 293T cells with the packaging plasmids pVSV-G and psPAX2. For each well of a 12-well plate, cells were infected with the harvested virus particles in the presence of 5 μg/ml polybrene by spinoculation at 450×g for 30 min at room temperature. Forty-eight hours later, cells were seeded into 96-well plates at the density of 0.5 cell/well with selection medium containing 2 μg/ml puromycin. After amplification for 2–3 weeks, the RELB−/− cells were verified by western blotting.
Viruses and infection
VSV-G pseudotyped HIV-1 (pNLENY1-ES-IRES and pNL4-3.Luc.env−) was produced by transfecting HEK 293T cells with proviral DNA constructs and pVSV-G plasmids. For VSV-G pseudotyped HIV-1, virus titer was determined by ELISA (Biomerieux) to quantify viral p24 amounts. For VSV-G pseudotyped HIV-1 infection, HeLa and Jurkat cells were spinoculated with VSVG-NL4-3.Luc.env− (20 ng p24). Luciferase assays were performed 48 h’ post infection.
For protein–protein interaction analysis, A total of 4 × 106 cells were transfected with various plasmids using the PEI reagent. After 48 h, cells (1 × 107–2.5 × 107) were harvested and lysed in immunoprecipitation buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 2 mM EDTA, 3% Glycerol, 1% Triton-X-100, protease inhibitor cocktail tablets complete, and EDTA-free [Roche]). Cell lysates were sonicated and centrifuged at 13,000×g for 10 min at 4 °C. Supernatants were incubated with antibodies (1 μg) for 3 h at 4 °C, then rotated with Protein A-agarose (Millipore, CAT# 16-125) for 3 h or overnight (for endogenous protein immunoprecipitation) at 4 °C. After being washed with lysis buffer for six times, the immunoprecipitated materials were boiled in 40 μl 2 × SDS loading buffer and subjected to western blotting (Ninety-five percent of cell extracts were used for the IP experiment, 1% of cell extracts were used as input for western blotting.).
Cell lysates or immunoprecipitated materials were resolved by SDS-PAGE and transferred onto the PVDF membranes (GE Healthcare). The membranes were blocked with 5% nonfat milk, then incubated with primary antibodies (0.1–0.5 μg/ml) at 4 °C overnight. After incubation with either goat anti-rabbit or goat anti-mouse secondary antibody conjugated with horseradish peroxidase (HRP) (0.05–0.1 μg/ml), membranes were treated with enhanced chemiluminescence reagents (Millipore). Protein signals were detected by exposure to X-ray films.
Immunofluorescence microscopy assay (IFA)
Indirect IFA was performed as previously described . Cells grown on poly-lysine-coated glass slides were fixed with 4% (wt/vol) paraformaldehyde in PBS for 10 min, followed by permeabilized with 0.1% Triton X-100 in PBS for 10 min. After incubation in the blocking buffer containing 3% FBS and 6% skim milk, cells were stained with primary antibodies (5 μg/ml, 2 h at room temperature), followed by incubation with FITC- or TRITC-conjugated secondary antibodies (2 μg/ml, 45 min at room temperature). DAPI was utilized to stain nuclei. Images were captured using Leica TCS SP5 laser scanning confocal microscope .
Cells were seeded on 12-well plates. The following day, they were transfected with reporter gene plasmid DNA along with the Renilla luciferase plasmid (phRluc-TK, Promega, CAT# E6921). Forty-eight hours after transfection, cells were harvested in lysis buffer, and luciferase assays were performed using the Dual-Luciferase reporter assay system (Promega, CAT# E1910) according to the manufacturer’s instructions. The relative luciferase activity was calculated by dividing the firefly luciferase activity by the Renilla luciferase activity. Three independent transfection experiments were performed.
Chromatin immunoprecipitation (ChIP) assay and quantitative real-time PCR
The ChIP-qPCR assay was performed in TZM-bl cells. The DNA-IP assay was performed in HeLa transfected with pHIV-1-LTR-luc. ChIP-qPCR assay and DNA-IP assay were performed using the Upstate Biotechnology ChIP assay kit (Millipore, CAT# 17-371RF) according to the manufacturer’s protocol. In brief, formaldehyde was added to the culture medium at a final concentration of 1% and incubated at 37 °C for 10 min, and the chromatin was immunoprecipitated with antibodies or control IgG antibodies. One-tenth of the lysates was kept to measure the amount of DNA present in different samples before immunoprecipitation. DNA was purified from both the immunoprecipitated and preimmune samples, diluted from 1: 10 to 1: 10,000, and subjected to PCR and a real-time PCR assay to detect HIV-1 LTR DNA using the primer pair LTR forward (5′-TAGAGTGGAGGTTTGACAGCCG-3′) and LTR reverse (5′-GTACAGGCAAAAAGCAGCTG-3′). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter DNA using the primer pair forward (5′-TACTAGCGGTTTTACGGGCG-3′) and LTR reverse (5′-TCGAACAGGAGGAGCAGAGAGCGA-3′) was also amplified from a ChIP assay that was performed with anti-RNA Pol II antibodies. The results served as a positive control. Real-time PCR was performed using FastStart Universal SYBR Green PCR Master Mix (Roche) according to the manufacturer’s instructions. Data were analyzed according to the ΔΔCt method and normalized to the input and IgG control.
Cells were harvested and fixed in 1% formaldehyde. YFP/GFP positive cells were scored with a FACSCalibur flow cytometer and analyzed using the FlowJo software.
Data were expressed as the mean ± standard deviation (SD) of three independent experiments, in which each assay was performed in triplicate. Data were compared using the unpaired two-tailed t test. P < 0.05 was considered significant, symbolized by *P < 0.05 and **P < 0.01. ns stands for not significant.
HIV-1 Tat interacts with RelB
Identification of protein sequences responsible for Tat and RelB interaction
RelB facilitates Tat-mediated HIV-1 LTR activation in TAR-independent manner
Previous studies have reported that Tat can transactivate the LTR through a TAR-independent mechanism [8, 9, 12]. We next examined whether TAR is necessary for RelB to enhance Tat activation. It is known that Tat binds to the bulge of TAR . We therefore mutated the bulge to abolish TAR-dependent Tat transactivation (Fig. 4b) . Results in Fig. 4c show that RelB overexpression still increased Tat-mediated LTR-mutTAR activation, and that this activation was significantly decreased by RelB knockout.
Tat and RelB are recruited to the HIV-1 promoter
Tat and Rel family transactivators were reported to play a critical role in transcription complex assembly at the preinitiation step . Given the recruitment of Tat and RNA Pol II to the HIV-1 LTR, we investigated the possibility that RelB might function as a transcriptional activator of the HIV-1 LTR, thereby reinforcing HIV-1 transactivation. To assess this possibility, we constructed the RelB knockout TZM-bl cell line and transfected it with Flag-Tat DNA (Fig. 5e). Results of ChIP assays with anti-RelB antibodies revealed enrichment of HIV-1 LTR DNA in control cells but not in RelB knockout cells (Fig. 5f). The recruitment of Tat to the HIV-1 LTR decreased as a result of RelB knockout (Fig. 5g), supporting the role of RelB in the recruitment of Tat to the HIV-1 LTR. With expression of Tat, knockout of RelB reduced the recruitment of RNA Pol II to the HIV-1 LTR. In the absence of Tat, knockout of RelB did not affect the recruitment of RNA Pol II (Fig. 5h). These results suggest that RelB assists the Tat-mediated recruitment of RNA Pol II to the LTR promoter.
RelB facilitates Tat-mediated HIV-1 LTR activation depends on the NF-κB sites
NF-κB elements are essential for RelB to enhance Tat recruitment to the LTR
RelB enhances HIV-1 gene expression
We next asked whether endogenous RelB has any effect on the transcription of HIV-1 during viral infection. To answer this question, we used VSV-G pseudotyped NL4-3.Luc.env− to infect HeLa cell lines and measured luciferase activity 40 h post infection. The results showed that knockout of RelB decreased HIV-1 p24 levels and reduced HIV-1 gene expression. Enzyme activity of luciferase of infected cells was significantly increased with the restoration of RelB expression in RelB knockout HeLa cells, which corroborated the effect of RelB overexpression on HIV-1 gene expression (Fig. 8c) (Additional file 4).
We further confirmed these findings in other HIV-1 permissive cell line by generating Jurkat cell lines that either overexpressed RelB or had RelB knocked out. We infected these Jurkat cells with VSV-G pseudotyped NLENY1-ES-IRES. pNLENY1-ES-IRES is a proviral DNA clone and express yellow fluorescent protein (YFP) from HIV-1 LTR promoter [32, 37]. The YFP sequence was inserted between the env and nef ORFs. An internal ribosome entry sequence (IRES) was inserted upstream of nef to direct the expression of Nef (Additional file 5) . We scored YFP positive cells by flow cytometry. Similar to the effect in HeLa cells, RelB overexpression increased the number of HIV positive cells, and RelB knockout reduced the number of HIV-1 positive cells (Fig. 8d, e). To validate this observation, we isolated PBMCs from healthy donors and examined effect of RelB on HIV-1 gene transcription. Again, RelB overexpression enhanced HIV-1 gene expression, and RelB knockdown reduced HIV-1 gene expression (Fig. 8f).
RelB facilitates reactivation of HIV-1 provirus in latently infected cells
The formation of a NF-κB p50/RelB/DNA complex suggests that RelB may recognize more diverse κB sequences . In this study, RelB efficiently increased Tat-dependent transactivation of the HIV-1 LTR. These data indicate that RelB is a potential Tat coactivator that facilitates the interaction between Tat and the transcription machinery on the HIV-1 LTR without TAR. Previous studies have suggested that Tat may be involved in facilitating and regulating RelA transcriptional activity [23, 53], but did not investigate whether Tat binds with RelB. One study reported that Tat induced RelB expression which inhibits cytokine production, possibly through the formation of transcriptionally inactive RelB/RelA complexes . In our research, we found that RelB enhances Tat recruitment to the LTR via NF-κB elements and Tat increased the recruitment of RelB and RNA Pol II to the LTR. With RelB knockout, the recruitment of Tat to the LTR reduced, RNA Pol II complex assembling to the LTR also diminished. These results support an important role for RelB in the regulation of LTR transcription initiation. Moreover, we used pseudotyped HIV-1 to examine the effect of RelB on HIV-1 gene transcription. The result showed that RelB enhanced HIV-1 gene expression during HIV-1 infection. Based on these data, we speculate that in HIV-1 infected cells, Tat and cellular RelB form a transcriptional complex which recognizes and binds to the NF-κB elements of the LTR and facilitates the recruitment of other coactivators to ultimately initiate LTR transcription.
Tat establishes interactions with many host proteins to promote HIV-1 propagation and HIV-1 pathogenesis. Tat also affects both the establishment and reversal of latency . For example, the deficiency of Tat protein contributes to latency mechanisms together with the deficiency of transcriptional factor NF-κB or NFAT, condensed chromatin structure, and epigenetic regulation [56–59]. It is possible that Tat facilitates the interaction of RelB and LTRs through chromatin structural remodeling in the LTR region. Our study support that, once Tat is produced, both transcription initiation and elongation are enhanced, which sustains continuous proviral gene expression. The interaction between RelB and Tat facilitates the assembly of transcription complexes on the LTR promoter (Fig. 10). We used the J-Lat A72 HIV-1 latency model to investigate the potential role of κB-specific transcriptional activators in the maintenance of viral transcription. Overexpressing Tat reactivated J-lat A72 cells, and RelB facilitated this reactivation. Based on our findings, RelB and Tat interaction contributes to proviral latency reactivation.
Similar to Tat, RelA stimulates transcription by recruiting P-TEFb to the initiating RNA Pol II [18, 60, 61]. Future work is needed to identify the specific mechanisms by which RelB binding regulates HIV-1 infection and the reactivation of latent proviruses.
Our study has discovered one more cellular factor that participates in the regulation of HIV-1 gene expression, which adds one more layer to the complex molecular mechanisms that center around Tat. It is unknown how these mechanisms and diverse molecular interactions function together. One possible scenario is that one mechanism may be more dominant over the other in a specific cell type, such as different subtypes of T cells, macrophage, dendritic cells, astrocytes and others, which depends on the availability and abundance of specific factors. It is also possible that HIV-1 needs several mechanisms to operate in concert to acquire an optimal level of viral gene expression, in response to different external stimuli. More studies are warranted to obtain further insights in this regards.
In summary, our results demonstrate that Tat interacts with RelB, RelB in turn enhances TAR-independent transactivation of HIV-1 gene expression. RelB plays an important role in Tat-mediated κB-site-dependent HIV-1 initial transcription. Thus, we have identified a TAR-independent, NF-κB-dependent step in the recruitment of RNA Pol II to the HIV-1 promoter and demonstrated that RelB is a critical factor in the regulation of HIV-1 transcription (Fig. 10). Our findings may inspire the development of new therapies that either prevent the reactivation of latent proviruses or stimulate reactivation and subsequently clear latently infected cells.
W. Qiao, J. Tan and M. Wang conceived the study. M. Wang carried out experiments, analyzed the data and wrote the manuscript. W. Yang and J. Wang generated Tat and RelB plasmids and participated in data analysis, respectively. Y. Chen performed Luciferase assay experiments. W. Qiao and J. Tan supervised the experimental work and participated in preparing the manuscript. All authors read and approved the final manuscript.
The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: TZM-bl cells from Dr. John C. Kappes, and Dr. Xiaoyun Wu, J-Lat GFP Clone A72 from Dr. Eric Verdin. pNL4-3.Luc.env− was kindly provided by Johnny J He (Department of Microbiology and Immunology, Indiana University School of Medicine, USA). NLENY1-ES-IRES construct was kindly provided by Dr. David Levy (University of Alabama at Birmingham, USA). We thank Dr. Lihong Shi (State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China) and Dr. Yushan Zhu (State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Protein Science, College of Life Sciences, Nankai University, China) for providing PBMCs and related regents.
The authors declare that they have no competing interests.
Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
Consent for publication
Ethics approval and consent to participate
The work was supported by the National Natural Science Foundation of China (81571988 and 31670151) and the Chinese Ministry of Health (2012ZX 10001006).
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem. 1999;274:28837–40.View ArticleGoogle Scholar
- Laspia MF, Rice AP, Mathews MB. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell. 1989;59:283–92.View ArticleGoogle Scholar
- Reeder JE, Kwak YT, McNamara RP, Forst CV, D’Orso I. HIV Tat controls RNA Polymerase II and the epigenetic landscape to transcriptionally reprogram target immune cells. Elife. 2015;4:e08955.View ArticleGoogle Scholar
- Rohr O, Marban C, Aunis D, Schaeffer E. Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells. J Leukoc Biol. 2003;74:736–49.View ArticleGoogle Scholar
- Pereira LA, Bentley K, Peeters A, Churchill MJ, Deacon NJ. A compilation of cellular transcription factor interactions with the HIV-1 LTR promoter. Nucleic Acids Res. 2000;28:663–8.View ArticleGoogle Scholar
- D’Orso I, Frankel AD. Tat acetylation modulates assembly of a viral-host RNA-protein transcription complex. Proc Natl Acad Sci USA. 2009;106:3101–6.View ArticleGoogle Scholar
- Yedavalli VS, Benkirane M, Jeang KT. Tat and trans-activation-responsive (TAR) RNA-independent induction of HIV-1 long terminal repeat by human and murine cyclin T1 requires Sp1. J Biol Chem. 2003;278:6404–10.View ArticleGoogle Scholar
- Berkhout B, Gatignol A, Rabson AB, Jeang KT. TAR-independent activation of the HIV-1 LTR: evidence that tat requires specific regions of the promoter. Cell. 1990;62:757–67.View ArticleGoogle Scholar
- Yang L, Morris GF, Lockyer JM, Lu M, Wang Z, Morris CB. Distinct transcriptional pathways of TAR-dependent and TAR-independent human immunodeficiency virus type-1 transactivation by Tat. Virology. 1997;235:48–64.View ArticleGoogle Scholar
- D’Orso I, Frankel AD. RNA-mediated displacement of an inhibitory snRNP complex activates transcription elongation. Nat Struct Mol Biol. 2010;17:815–21.View ArticleGoogle Scholar
- Wilhelm E, Doyle MC, Nzaramba I, Magdzinski A, Dumais N, Bell B. CTGC motifs within the HIV core promoter specify Tat-responsive pre-initiation complexes. Retrovirology. 2012;9:62.View ArticleGoogle Scholar
- Das AT, Harwig A, Berkhout B. The HIV-1 Tat protein has a versatile role in activating viral transcription. J Virol. 2011;85:9506–16.View ArticleGoogle Scholar
- van der Velden GJ, Klaver B, Das AT, Berkhout B. Upstream AUG codons in the simian immunodeficiency virus SIVmac239 genome regulate Rev and Env protein translation. J Virol. 2012;86:12362–71.View ArticleGoogle Scholar
- Donahue DA, Wainberg MA. Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology. 2013;10:11.View ArticleGoogle Scholar
- Kim HY, Choi BS, Kim SS, Roh TY, Park J, Yoon CH. NUCKS1, a novel Tat coactivator, plays a crucial role in HIV-1 replication by increasing Tat-mediated viral transcription on the HIV-1 LTR promoter. Retrovirology. 2014;11:67.View ArticleGoogle Scholar
- Bruce JW, Reddington R, Mathieu E, Bracken M, Young JA, Ahlquist P. ZASC1 stimulates HIV-1 transcription elongation by recruiting P-TEFb and TAT to the LTR promoter. PLoS Pathog. 2013;9:e1003712.View ArticleGoogle Scholar
- Bachu M, Yalla S, Asokan M, Verma A, Neogi U, Sharma S, Murali RV, Mukthey AB, Bhatt R, Chatterjee S, et al. Multiple NF-kappaB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance. J Biol Chem. 2012;287:44714–35.View ArticleGoogle Scholar
- Heusinger E, Kirchhoff F. Primate lentiviruses modulate NF-kappaB activity by multiple mechanisms to fine-tune viral and cellular gene expression. Front Microbiol. 2017;8:198.View ArticleGoogle Scholar
- Jiang G, Dandekar S. Targeting NF-kappaB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. AIDS Res Hum Retroviruses. 2015;31:4–12.View ArticleGoogle Scholar
- Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, Maestre AM, Manganaro L, Vamos M, Teriete P, et al. BIRC2/cIAP1 is a negative regulator of HIV-1 transcription and can be targeted by Smac mimetics to promote reversal of viral latency. Cell Host Microbe. 2015;18:345–53.View ArticleGoogle Scholar
- Taylor JP, Pomerantz RJ, Oakes JW, Khalili K, Amini S. A CNS-enriched factor that binds to NF-kappa B and is required for interaction with HIV-1 tat. Oncogene. 1995;10:395–400.PubMedGoogle Scholar
- Dandekar DH, Ganesh KN, Mitra D. HIV-1 Tat directly binds to NFkappaB enhancer sequence: role in viral and cellular gene expression. Nucleic Acids Res. 2004;32:1270–8.View ArticleGoogle Scholar
- Fiume G, Vecchio E, De Laurentiis A, Trimboli F, Palmieri C, Pisano A, Falcone C, Pontoriero M, Rossi A, Scialdone A, et al. Human immunodeficiency virus-1 Tat activates NF-kappaB via physical interaction with IkappaB-alpha and p65. Nucleic Acids Res. 2012;40:3548–62.View ArticleGoogle Scholar
- Millet P, McCall C, Yoza B. RelB: an outlier in leukocyte biology. J Leukoc Biol. 2013;94:941–51.View ArticleGoogle Scholar
- Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693–733.View ArticleGoogle Scholar
- McCall CE, Yoza BK. Gene silencing in severe systemic inflammation. Am J Respir Crit Care Med. 2007;175:763–7.View ArticleGoogle Scholar
- Madge LA, May MJ. The NFkappaB paradox: RelB induces and inhibits gene expression. Cell Cycle. 2011;10:6–7.View ArticleGoogle Scholar
- Vallabhapurapu SD, Noothi SK, Pullum DA, Lawrie CH, Pallapati R, Potluri V, Kuntzen C, Khan S, Plas DR, Orlowski RZ, et al. Transcriptional repression by the HDAC4–RelB–p52 complex regulates multiple myeloma survival and growth. Nat Commun. 2015;6:8428.View ArticleGoogle Scholar
- Wang J, Tan J, Guo H, Zhang Q, Jia R, Xu X, Geng Y, Qiao W. Bovine foamy virus transactivator BTas interacts with cellular RelB to enhance viral transcription. J Virol. 2010;84:11888–97.View ArticleGoogle Scholar
- Liu RK, Tan J, Lin YQ, Jia R, Yang W, Liang C, Geng YQ, Qiao WT. HIV-1 Vpr activates both canonical and noncanonical NF-kappa B pathway by enhancing the phosphorylation of IKK alpha/beta. Virology. 2013;439:47–56.View ArticleGoogle Scholar
- Motai Y, Takahashi M, Takachi T, Higuchi M, Hara T, Mizuguchi M, Aoyagi Y, Terai S, Tanaka Y, Fujii M. Human T-cell leukemia virus type 1 (HTLV-1) Tax1 oncoprotein but not HTLV-2 Tax2 induces the expression of OX40 ligand by interacting with p52/p100 and RelB. Virus Genes. 2016;52:4–13.View ArticleGoogle Scholar
- Liang Z, Liu R, Zhang H, Zhang S, Hu X, Tan J, Liang C, Qiao W. GADD45 proteins inhibit HIV-1 replication through specific suppression of HIV-1 transcription. Virology. 2016;493:1–11.View ArticleGoogle Scholar
- Zhao X, Qian L, Qi D, Zhou D, Shen W, Liu Y, Liu C, Kong X. The 57th amino acid conveys the differential subcellular localization of human immunodeficiency virus-1 Tat derived from subtype B and C. Virus Genes. 2016;52:179–88.View ArticleGoogle Scholar
- Wang J, Tan J, Zhang X, Guo H, Zhang Q, Guo T, Geng Y, Qiao W. BFV activates the NF-kappaB pathway through its transactivator (BTas) to enhance viral transcription. Virology. 2010;400:215–23.View ArticleGoogle Scholar
- Liu R, Lin Y, Jia R, Geng Y, Liang C, Tan J, Qiao W. HIV-1 Vpr stimulates NF-kappaB and AP-1 signaling by activating TAK1. Retrovirology. 2014;11:45.View ArticleGoogle Scholar
- Park IW, Han C, Song X, Green LA, Wang T, Liu Y, Cen C, Song X, Yang B, Chen G, He JJ. Inhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plants. BMC Complement Altern Med. 2009;9:29.View ArticleGoogle Scholar
- Levy DN, Aldrovandi GM, Kutsch O, Shaw GM. Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A. 2004;101:4204–9.View ArticleGoogle Scholar
- Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281–308.View ArticleGoogle Scholar
- Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol. 1998;72:2855–64.PubMedPubMed CentralGoogle Scholar
- Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O’Brien WA, Ratner L, Kappes JC, Shaw GM, Hunter E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol. 2000;74:8358–67.View ArticleGoogle Scholar
- Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896–905.View ArticleGoogle Scholar
- Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J. 2003;22:1868–77.View ArticleGoogle Scholar
- Jordan A, Defechereux P, Verdin E. The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation. EMBO J. 2001;20:1726–38.View ArticleGoogle Scholar
- Richter S, Cao H, Rana TM. Specific HIV-1 TAR RNA loop sequence and functional groups are required for human cyclin T1-Tat-TAR ternary complex formation. Biochemistry. 2002;41:6391–7.View ArticleGoogle Scholar
- Beauparlant P, Kwon H, Clarke M, Lin R, Sonenberg N, Wainberg M, Hiscott J. Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication. J Virol. 1996;70:5777–85.PubMedPubMed CentralGoogle Scholar
- Brady J, Kashanchi F. Tat gets the “green” light on transcription initiation. Retrovirology. 2005;2:69.View ArticleGoogle Scholar
- Shojania S, O’Neil JD. HIV-1 Tat is a natively unfolded protein: the solution conformation and dynamics of reduced HIV-1 Tat-(1-72) by NMR spectroscopy. J Biol Chem. 2006;281:8347–56.View ArticleGoogle Scholar
- Pumfery A, Deng L, Maddukuri A, de la Fuente C, Li H, Wade JD, Lambert P, Kumar A, Kashanchi F. Chromatin remodeling and modification during HIV-1 Tat-activated transcription. Curr HIV Res. 2003;1:343–62.View ArticleGoogle Scholar
- Tahirov TH, Babayeva ND, Varzavand K, Cooper JJ, Sedore SC, Price DH. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature. 2010;465:747–51.View ArticleGoogle Scholar
- Gu J, Babayeva ND, Suwa Y, Baranovskiy AG, Price DH, Tahirov TH. Crystal structure of HIV-1 Tat complexed with human P-TEFb and AFF4. Cell Cycle. 2014;13:1788–97.View ArticleGoogle Scholar
- Jean MJ, Power D, Kong W, Huang H, Santoso N, Zhu J: Identification of HIV-1 Tat-associated proteins contributing to HIV-1 transcription and latency. Viruses. 2017, 9.Google Scholar
- Moorthy AK, Huang DB, Wang VY, Vu D, Ghosh G. X-ray structure of a NF-kappaB p50/RelB/DNA complex reveals assembly of multiple dimers on tandem kappaB sites. J Mol Biol. 2007;373:723–34.View ArticleGoogle Scholar
- Lusic M, Marcello A, Cereseto A, Giacca M. Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter. EMBO J. 2003;22:6550–61.View ArticleGoogle Scholar
- Kiebala M, Polesskaya O, Yao Z, Perry SW, Maggirwar SB. Nuclear factor-kappa B family member RelB inhibits human immunodeficiency virus-1 Tat-induced tumor necrosis factor-alpha production. PLoS ONE. 2010;5:e11875.View ArticleGoogle Scholar
- Kamori D, Ueno T. HIV-1 Tat and viral latency: what we can learn from naturally occurring sequence variations. Front Microbiol. 2017;8:80.View ArticleGoogle Scholar
- Kinoshita S, Chen BK, Kaneshima H, Nolan GP. Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells. Cell. 1998;95:595–604.View ArticleGoogle Scholar
- Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature. 1987;326:711–3.View ArticleGoogle Scholar
- Kauder SE, Bosque A, Lindqvist A, Planelles V, Verdin E. Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog. 2009;5:e1000495.View ArticleGoogle Scholar
- Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 2006;25:139–49.View ArticleGoogle Scholar
- Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell. 2001;8:327–37.View ArticleGoogle Scholar
- McNamara RP, McCann JL, Gudipaty SA, D’Orso I. Transcription factors mediate the enzymatic disassembly of promoter-bound 7SK snRNP to locally recruit P-TEFb for transcription elongation. Cell Rep. 2013;5:1256–68.View ArticleGoogle Scholar